Literature DB >> 10527709

Roles of platelet-activating factor, interleukin-1beta and interleukin-6 in intestinal barrier dysfunction induced by mesenteric arterial ischemia and reperfusion.

Z Sun1, X Wang, A Lasson, A Börjesson, P Leveau, P Haraldsen, R Andersson.   

Abstract

BACKGROUND: Platelet-activating factor (PAF), cytokines, proteases, and other factors are probably involved in the development of gut barrier dysfunction following intestinal ischemia and reperfusion (I/R), although the act underlying pathophysiological mechanisms has not yet been fully clarified. The aim of the present study was to clarify the relationship of intestinal barrier integrity to systemic levels of interleukin-1beta, interleukin-6, and protease inhibitor levels and local leukocyte accumulation in a rat model of intestinal ischemia for 40 min followed by 3 or 12 h reperfusion, with or without treatment with a PAF inhibitor.
METHODS: Myeloperoxidase (MPO) content in the small intestinal mucosa, serum levels of interleukin-1beta and -6, and plasma protease inhibitors, and intestinal endothelial and epithelial permeability were assessed, with or without treatment with the PAF antagonist lexipafant.
RESULTS: Intestinal I/R resulted in intestinal barrier dysfunction with pronounced plasma leakage to the intestinal lumen, the leakage being aggravated following a longer reperfusion period. Proteolytic plasma activity was evident by low levels of the plasma protease inhibitors measured. MPO content increased significantly after I/R, as did serum levels of interleukin-1beta and -6, without difference between the two periods of reperfusion. Treatment with the PAF inhibitor lexipafant partly, though not fully, restored the changes caused by I/R.
CONCLUSION: PAF seems to be involved in the release of cytokines, such as interleukin-1 and -6, consumption of protease inhibitors, and impaired intestinal barrier integrity seen following intestinal I/R. Treatment with a PAF antagonist was effective in restoring the changes caused by intestinal I/R, though not reaching complete normal levels. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10527709     DOI: 10.1006/jsre.1999.5746

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  12 in total

1.  The effects of PAF antagonist on intestinal mucosal microcirculation after burn in rats.

Authors:  Pei-Wu Yu; Guang Xia Xiao; Li-Xin Zhou; Zi-Qiang Wang
Journal:  World J Gastroenterol       Date:  2000-12       Impact factor: 5.742

2.  Enteral nutrition prevents remote organ injury and death after a gut ischemic insult.

Authors:  K Fukatsu; B L Zarzaur; C D Johnson; A H Lundberg; H G Wilcox; K A Kudsk
Journal:  Ann Surg       Date:  2001-05       Impact factor: 12.969

3.  IL-1beta-induced increase in intestinal epithelial tight junction permeability is mediated by MEKK-1 activation of canonical NF-kappaB pathway.

Authors:  Rana Al-Sadi; Dongmei Ye; Hamid M Said; Thomas Y Ma
Journal:  Am J Pathol       Date:  2010-11       Impact factor: 4.307

4.  Protective effects of a new stable, highly active SOD mimetic, M40401 in splanchnic artery occlusion and reperfusion.

Authors:  S Cuzzocrea; E Mazzon; L Dugo; A P Caputi; K Aston; D P Riley; D Salvemini
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

5.  Lipopolysaccharide-Induced Increase in Intestinal Permeability Is Mediated by TAK-1 Activation of IKK and MLCK/MYLK Gene.

Authors:  Meghali Nighot; Manmeet Rawat; Rana Al-Sadi; Eliseo F Castillo; Prashant Nighot; Thomas Y Ma
Journal:  Am J Pathol       Date:  2019-02-01       Impact factor: 4.307

6.  Lidocaine inhibits secretion of IL-8 and IL-1beta and stimulates secretion of IL-1 receptor antagonist by epithelial cells.

Authors:  M Lahav; M Levite; L Bassani; A Lang; H Fidder; R Tal; S Bar-Meir; L Mayer; Y Chowers
Journal:  Clin Exp Immunol       Date:  2002-02       Impact factor: 4.330

7.  Comparative protection against rat intestinal reperfusion injury by a new inhibitor of sPLA2, COX-1 and COX-2 selective inhibitors, and an LTC4 receptor antagonist.

Authors:  Thiruma V Arumugam; Naomi Arnold; Lavinia M Proctor; Michelle Newman; Robert C Reid; Karl A Hansford; David P Fairlie; Ian A Shiels; Stephen M Taylor
Journal:  Br J Pharmacol       Date:  2003-07-29       Impact factor: 8.739

8.  Effects of hyperbaric oxygen on intestinal mucosa apoptosis caused by ischemia-reperfusion injury in rats.

Authors:  Shi-Hui Zhou; Yan-Fei Sun; Gang Wang
Journal:  World J Emerg Med       Date:  2012

9.  Comparative anti-inflammatory activities of antagonists to C3a and C5a receptors in a rat model of intestinal ischaemia/reperfusion injury.

Authors:  Lavinia M Proctor; Thiruma V Arumugam; Ian Shiels; Robert C Reid; David P Fairlie; Stephen M Taylor
Journal:  Br J Pharmacol       Date:  2004-05-24       Impact factor: 8.739

10.  Roles of BN52021 in platelet-activating factor pathway in inflammatory MS1 cells.

Authors:  Shi-Hai Xia; Xiao-Hui Xiang; Kai Chen; Wei Xu
Journal:  World J Gastroenterol       Date:  2013-07-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.